| EMA number | EMEA/H/C/003861 |
| ATC code | H05AA03 |
| Authorisation | 24 April 2017 |
| Withdrawn | 1 July 2026 |
| Revision | 18 |
Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.